Avalo Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Avalo Therapeutics has a total shareholder equity of $22.7M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $98.5M and $75.7M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$81.86m |
| Equity | US$22.73m |
| Total liabilities | US$75.72m |
| Total assets | US$98.46m |
Recent financial health updates
Recent updates
Avalo to get ~15M upfront in license deal with Apollo Therapeutics for AVTX-007
Aug 01Avalo Therapeutics announces one-for-twelve reverse stock split
Jul 06Is Cerecor (NASDAQ:CERC) A Risky Investment?
Aug 10
Cerecor enters into $35M debt financing agreement with Horizon Technology Finance
Jun 07What Kind Of Investors Own Most Of Cerecor Inc. (NASDAQ:CERC)?
Mar 10Have Insiders Been Buying Cerecor Inc. (NASDAQ:CERC) Shares?
Jan 18Armistice Capital adds 2.5M Cerecor shares for $6.5M
Jan 13Cerecor slumps 12% on stock and pre-funded warrants offering
Jan 07Financial Position Analysis
Short Term Liabilities: AVTX's short term assets ($86.1M) exceed its short term liabilities ($60.7M).
Long Term Liabilities: AVTX's short term assets ($86.1M) exceed its long term liabilities ($15.0M).
Debt to Equity History and Analysis
Debt Level: AVTX is debt free.
Reducing Debt: AVTX has no debt compared to 5 years ago when its debt to equity ratio was 84%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AVTX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: AVTX has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 12.2% each year.